Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee

NCT04119687 is registered in ClinicalTrials.gov with Pacira Pharmaceuticals, Inc as lead sponsor.

NCT NCT04119687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04119687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee
Lead sponsor
Pacira Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 2, 2020
Completion date
November 28, 2026
Enrollment
72 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee